Health alert Status: Active Date issued: 19 June 2026 Issued by: Dr Caroline McElnay, Chief Health Officer Issued to: Health professionals and the Victorian community Key messages The department has been notified of six cases of acute liver toxicity associated with an unapproved peptide product in Australia, labelled Retatrutide
GHK-CU/BPC-157/TB-500/KPV KLOW Blend KLOW Blend is a multi-component, research-grade peptide formulation combining GHK-Cu, BPC-157, TB-500, and KPV in a single lyophilized vial (~80 mg total)
Increase growth hormone release Peptides stimulate your body to produce more growth hormone, a key hormone that regulates metabolism, muscle growth, and fat burning
0.25 to 0.5 mg daily, subcutaneous near injury 2.5 mg twice weekly (5 mg total) for weeks 1-4 2.0 to 2.5 mg weekly for weeks 5-8 6 to 8 weeks total Use separate vials and syringes
Narita, Redistribution of the Lamin B1 genomic binding profile affects rearrangement of heterochromatic domains and SAHF formation during senescence
In fact, its use shot up when placed on the list of unapproved substances
